Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Invega (paliperidone), Xeplion (paliperidone palmitate), Risperdal, Risperdal Consta (risperidone) - Important Safety Information from Janssen as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
08/10/2013
Problem Or Issue:
Important Safety Information communication from Janssen on the risk of intraoperative floppy iris syndrome (IFIS) related to treatment with risperidone, paliperidone or paliperidone palmitate in patients undergoing cataract surgery.
Important Safety Information - Invega (paliperidone), Xeplion (paliperidone palmitate), Risperdal, Risperdal Consta (risperidone)
« Back
Date Printed: 07/05/2024